Erik S Mittra
Affiliation: Stanford University
- Comparative morphometrics of the primate apical tuftErik S Mittra
Division of Nuclear Medicine, Stanford University, Stanford, CA 94305, USA
Am J Phys Anthropol 134:449-59. 2007..The implications of these findings for hypotheses about the association of apical tuft size and tool making in the hominin fossil record are discussed...
- A case of three synchronous primary tumors demonstrated by F-18 FDG PETErik Mittra
Nuclear Medicine Service, VA Palo Alto Health Care System, Palo Alto, California, USA
Clin Nucl Med 32:666-7. 2007..A staging PET scan additionally showed increased left tonsillar uptake. Subsequent biopsy confirmed squamous cell carcinoma of the left tonsil. The demonstration of 3 synchronous primaries by PET is probably rare...
- Concurrent metabolic and osseous metastatic disease on a Tc99m-MDP bone scanErik Mittra
Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
Eur J Nucl Med Mol Imaging 34:2150. 2007
- Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levelsErik S Mittra
Molecular Imaging Program, Department of Radiology, Division of Nuclear Medicine, Stanford Hospital and Clinics, 300 Pasteur Dr, Room H2200, Stanford, CA 94305 5281, USA
Radiology 260:182-91. 2011....
- Positron emission tomography/computed tomography: the current technology and applicationsErik Mittra
Division of Nuclear Medicine, Stanford Hospital and Clinics, 300 Pasteur Drive, Room H0101, Stanford, CA 94305, USA
Radiol Clin North Am 47:147-60. 2009..Additionally, novel radiopharmeuticals are under development, many of which are target cellular processes that are more specific than glucose metabolism...
- Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancyFrank I Lin
Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Dr, Room H 2230, Stanford, CA 94305, USA
Eur J Nucl Med Mol Imaging 39:262-70. 2012..In the current study, we compared the clinical usefulness of a combined (18)F-FDG/(18)F-NaF PET/CT scan with that of a separate (18)F-FDG-only PET/CT scan...
- 18F-FDG PET/CT evaluation of patients with ovarian carcinomaAndrei H Iagaru
Department of Radiolog, Stanford Hospital and Clinics, Stanford, CA, USA
Nucl Med Commun 29:1046-51. 2008..Therefore, we were prompted to review our experience with PET/CT in the management of patients with ovarian carcinoma...
- Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase studyAndrei Iagaru
Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California, USA
J Nucl Med 50:501-5. 2009..Sodium (18)F was previously used for bone imaging and can be used as a PET/CT skeletal tracer. The combined administration of (18)F and (18)F-FDG in a single PET/CT study for cancer detection has not been reported to date...
- FDG-PET/CT in cancers of the head and neck: what is the definition of whole body scanning?Andrei Iagaru
Stanford Hospital and Clinics, Division of Nuclear Medicine, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305, USA
Mol Imaging Biol 13:362-7. 2011..e., eyes to thighs) may yield little additional information. Therefore, we were prompted to review our experience with PET/computed tomography (CT) in the management of patients with HNSCC and NPC...
- Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRIErik S Mittra
Authors Affiliations Molecular Imaging Program, Department of Radiology, System Medicine, Department of Pediatrics, Division of Neuropathology, Department of Pathology, Merck Research Laboratories, Palo Alto, California AVEO Pharmaceuticals Inc, Cambridge, Massachusettes and Bio X Program, Department of Bioengineering, Department of Materials Science and Engineering, Stanford University, Stanford
Clin Cancer Res 19:5711-21. 2013..Ficlatuzumab is a novel therapeutic agent targeting the hepatocyte growth factor (HGF)/c-MET pathway. We summarize extensive preclinical work using this agent in a mouse brain orthotopic model of glioblastoma...
- Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECTMarnix G E H Lam
Division of Interventional Radiology, Stanford University School of Medicine, Stanford, California
J Nucl Med 54:2055-61. 2013..Planning hepatic (90)Y radioembolization activity requires balancing toxicity with efficacy. We developed a dual-tracer SPECT fusion imaging protocol that merges data on radioactivity distribution with physiologic liver mapping...
- 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphomaAndrei Iagaru
Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
Mol Imaging Biol 12:198-203. 2010..Both target CD20 receptors present on the surface of lymphocytes. We present our clinical experience with Bexxar and Zevalin in the management of low-grade refractory or relapsed NHL...
- Recurrent silent thyroiditis: a report of four patients and review of the literatureErik S Mittra
Division of Nuclear Medicine, Stanford University Medical Center and Clinics, Stanford, California 94305, USA
Thyroid 17:671-5. 2007..Three were treated with radioablative iodine therapy during the recovery phase of an episode; they became hypothyroid and take replacement l-thyroxine. They have remained symptom free...
- Evaluation of trabecular mechanical and microstructural properties in human calcaneal bone of advanced age using mechanical testing, microCT, and DXAErik Mittra
Department of Radiology Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Dr, Rm H0101, Stanford, CA 94305, USA
J Biomech 41:368-75. 2008..Ultimate stress, however, is better correlated with trabecular number than thickness. As such, primary prevention of osteoporosis may be more important than later countermeasures for bone loss...